FDA NDC
JAKAFI XR
This name is from the loaded FDA file.
Source: FDA NDC Directory, live from openFDA. Publisher page
- NDC
- 50881-044
- Proprietary name
- JAKAFI XR
- Nonproprietary name
- ruxolitinib
- Labeler
- Incyte Corporation
- Dosage form
- TABLET, EXTENDED RELEASE
- Strength
- 44 mg/1
Run it in Rivvi
Which 2027 plans near you dropped or restricted ruxolitinib?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan, from the CMS Part D files.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.